Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional meglumine antimoniate with or without topical imiquimod for cutaneous leishmaniasis
RBR-3j6jwg3Phase 3Recruiting
- Sponsor
- Ebserh
- Start
- Jun 2024
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cutaneous leishmaniasis (CL) comparing Intralesional meglumine antimoniate + topical imiquimod with Intralesional meglumine antimoniate (2 arms). Started Jun 2024; status: recruiting.
02
Drugs
meglumine antimoniateimiquimod
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on RBR-3j6jwg3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3j6jwg3.